![](https://endpts.com/wp-content/uploads/2021/09/Daniel-ODay-Getty-scaled.jpg)
Dan O'Day, Gilead CEO (Jim Watson/AFP via Getty Images)
European study finds that Gilead's Covid-19 antiviral remdesivir shows no clinical benefit
Gilead’s remdesivir — or Veklury, as it’s marketed in the US — raked in around $2.8 billion last year as the only FDA-approved antiviral to treat Covid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.